Comparison of the transcriptional changes of RAGs in DRGs with systemic MS-275 treatment versus peripheral axotomya
| Genes | MS-275 (fold Δ ± SEM)b | Peripheral axotomy (fold Δ ± SEM)c | References | |
|---|---|---|---|---|
| No significant change with MS-275 treatment | Smad1 | 1.3 ± 0.2 | 2.28 ± 0.97 | Current study |
| Atf3 | 1.0 ± 0.3 | 56.9 ± 3.7 | Current study | |
| Gap43 | 1.7 ± 0.9 | 1.7 ± 0.7 | Current study | |
| Integrin | 1.1 ± 0.1 | 2.4 ± 0.3 | Current study | |
| Atf4 | 1.4 ± 0.8 | 1.34 ± 0.29 | Current study | |
| C/ebp | 0.9 ± 0.3 | 2.05 ± 0.14 | Current study | |
| Creb | 1.1 ± 0.1 | Not determined | ||
| Csrp3 | 1.5 ± 0.4 | Not determined | ||
| IL6 | 1.1 ± 0.1 | 4.2 (18 h) | Cao et al., 2006 | |
| Isl1 | 0.7 ± 0.2 | 0.67 ± 0.49 | Current study | |
| Jun | 0.7 ± 0.4 | 1.81 ± 0.82 | Current study | |
| Klf7 | 0.98 ± 0.2 | 1.83 ± 0.26 | Current study | |
| Discordant change | Arg1 | 0.6 ± 0.1 | 15.3 ± 1.5 (2w) | Ylera et al., 2009 |
| Crem | 0.05 ± 0.1 | 1.86 ± 0.74 | Current study | |
| Fos | 0.02 ± 0.01 | 2.31 ± 0.47 | Current study | |
| Concordant change | Sprr1a | 10.2 ± 2.9 | 212.5 ± 22.3 | Current study |
| Npy | 11.2 ± 6.0 | 80.4 ± 10.8 | Current study | |
| Galanin | 2.5 ± 1.0 | 16.9 ± 0.5 | Current study | |
| Vip | 8.7 ± 0.8 | 4.8 ± 0.4 | Current study | |
| Cap23 | 2.2 ± 0.3 | 2.0 ± 0.3 | Current study | |
| Krox4 | 1.7 ± 0.4 | 2.7 ± 0.8 | Current study | |
| Sox11 | 2.2 ± 0.2 | 6.7 ± 0.46 | Current study | |
| Zpf91 | 1.7 ± 0.1 | 1.6 ± 0.3 | Current study | |
| HoxD1 | 0.3 ± 0.3 | 0.4 ± 0.17 | Zou et al., 2009 | |
| Onecut1 | 0.15 ± 0.005 | 0.47 ± 0.21 | Current study |
↵aList of relative fold changes of the mRNA levels by qRT-PCR of 25 RAGs in DRGs with MS-275 versus vehicle treatment, or with peripheral axotomy versus no lesion after the indicated time periods. Results are shown as mean ± SEM.
↵bSix hours after the last of the four daily subcutaneous injections of MS-275.
↵cTwenty-four hours after peripheral axotomy, unless otherwise specified in parentheses.